MedPath

QBIOTICS GROUP LIMITED

πŸ‡¦πŸ‡ΊAustralia
Ownership
-
Employees
-
Market Cap
-
Website

A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma

Phase 2
Recruiting
Conditions
Soft Tissue Sarcoma
Interventions
Drug: Tigilanol Tiglate
First Posted Date
2023-03-06
Last Posted Date
2024-07-10
Lead Sponsor
QBiotics Group Limited
Target Recruit Count
10
Registration Number
NCT05755113
Locations
πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Cancer Centre, New York, New York, United States

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

Phase 2
Recruiting
Conditions
Head and Neck Cancer
Interventions
Drug: Tigilanol Tiglate
First Posted Date
2022-11-08
Last Posted Date
2024-01-17
Lead Sponsor
QBiotics Group Limited
Target Recruit Count
37
Registration Number
NCT05608876
Locations
πŸ‡¦πŸ‡Ί

The Kinghorn Cancer Centre, Sydney, New South Wales, Australia

πŸ‡¬πŸ‡§

East and North Hertfordshire NHS Trust (Incorporating Mount Vernon Cancer Centre) of Lister Hospital, Stevenage, Hertfordshire, United Kingdom

πŸ‡¬πŸ‡§

The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom

and more 4 locations

A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

Phase 2
Terminated
Conditions
Melanoma
Interventions
Drug: tigilanol tiglate
First Posted Date
2022-02-10
Last Posted Date
2023-04-19
Lead Sponsor
QBiotics Group Limited
Target Recruit Count
1
Registration Number
NCT05234437
Locations
πŸ‡¦πŸ‡Ί

Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia

πŸ‡¦πŸ‡Ί

Cairns and Hinterland Hospital and Health Service, Cairns, Queensland, Australia

πŸ‡¦πŸ‡Ί

Metro South Hospital and Health Service via Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Phase 1
Terminated
Conditions
Melanoma
Interventions
Drug: tigilanol tiglate
Drug: pembrolizumab
First Posted Date
2021-04-08
Last Posted Date
2023-04-18
Lead Sponsor
QBiotics Group Limited
Target Recruit Count
3
Registration Number
NCT04834973
Locations
πŸ‡¦πŸ‡Ί

Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia

πŸ‡¦πŸ‡Ί

Cairns and Hinterland Hospital and Health Service, Cairns, Queensland, Australia

Β© Copyright 2025. All Rights Reserved by MedPath